Platelet reactivity index (%) (pharmacodynamics analysis set)
| Visit . | Time point . | Ticagrelor . | Placebo . | |||
|---|---|---|---|---|---|---|
| n . | Median (minimum, maximum) . | Platelet inhibition, %* . | n . | Median (minimum, maximum) . | ||
| Baseline | Predose | 68 | 84.8 (–5.9, 100.0) | 59 | 89.7 (–1.8, 100.0) | |
| Day 0 | 2 h postdose | 67 | 41.1 (1.7, 100.0) | 43.9 | 56 | 91.7 (2.7, 100.0) |
| Week 4 | Predose | 50 | 56.3 (–5.4, 96.7) | 25.1 | 43 | 91.6 (24.6, 100.0) |
| 2 h postdose | 50 | 40.0 (–0.8, 100.0) | 54.1 | 43 | 93.9 (10.5, 100.0) | |
| Month 6 | Predose | 45 | 47.2 (12.6, 100.0) | 34.9 | 43 | 90.2 (–7.6, 97.9) |
| 2 h postdose | 45 | 29.2 (0.0, 85.9) | 55.7 | 43 | 91.4 (7.5, 97.1) | |
| Visit . | Time point . | Ticagrelor . | Placebo . | |||
|---|---|---|---|---|---|---|
| n . | Median (minimum, maximum) . | Platelet inhibition, %* . | n . | Median (minimum, maximum) . | ||
| Baseline | Predose | 68 | 84.8 (–5.9, 100.0) | 59 | 89.7 (–1.8, 100.0) | |
| Day 0 | 2 h postdose | 67 | 41.1 (1.7, 100.0) | 43.9 | 56 | 91.7 (2.7, 100.0) |
| Week 4 | Predose | 50 | 56.3 (–5.4, 96.7) | 25.1 | 43 | 91.6 (24.6, 100.0) |
| 2 h postdose | 50 | 40.0 (–0.8, 100.0) | 54.1 | 43 | 93.9 (10.5, 100.0) | |
| Month 6 | Predose | 45 | 47.2 (12.6, 100.0) | 34.9 | 43 | 90.2 (–7.6, 97.9) |
| 2 h postdose | 45 | 29.2 (0.0, 85.9) | 55.7 | 43 | 91.4 (7.5, 97.1) | |
Platelet reactivity index assessed by vasodilator-stimulated phosphoprotein assay. Data from month 12 and month 18 are not included owing to the small number of observations (ticagrelor month 12: predose, n = 8; postdose, n = 9; ticagrelor month 18: predose and postdose, n = 1. Placebo month 12: predose and postdose, n = 5; placebo month 18: predose and postdose, n = 0).
Relative to baseline median. Manually derived as: median change from baseline (%)/median platelet reactivity index (%) at baseline × 100, where median platelet reactivity index (%) at baseline is 84.8.